BSE Live
Dec 05, 16:01Prev. Close
6470.60
Open Price
6470.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 05, 15:54Prev. Close
6469.00
Open Price
6467.00
Bid Price (Qty.)
6473.50 (6)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Divis Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 53.00 | 53.00 | 53.09 | 53.09 | 53.09 | |
| Total Share Capital | 53.00 | 53.00 | 53.09 | 53.09 | 53.09 | |
| Reserves and Surplus | 14,916.00 | 13,518.00 | 12,714.00 | 11,675.09 | 9,241.52 | |
| Total Reserves and Surplus | 14,916.00 | 13,518.00 | 12,714.00 | 11,675.09 | 9,241.52 | |
| Total Shareholders Funds | 14,969.00 | 13,571.00 | 12,767.09 | 11,728.18 | 9,294.61 | |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 509.00 | 582.00 | 537.21 | 421.40 | 338.06 | |
| Other Long Term Liabilities | 2.00 | 2.00 | 2.77 | 2.87 | 3.69 | |
| Long Term Provisions | 0.00 | 37.00 | 30.62 | 26.71 | 25.25 | |
| Total Non-Current Liabilities | 511.00 | 621.00 | 570.60 | 450.98 | 367.00 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 2.00 | 0.00 | 0.00 | 0.00 | 0.35 | |
| Trade Payables | 910.00 | 824.00 | 762.51 | 795.70 | 763.20 | |
| Other Current Liabilities | 486.00 | 447.00 | 333.65 | 395.70 | 346.40 | |
| Short Term Provisions | 54.00 | 7.00 | 4.92 | 4.15 | 2.51 | |
| Total Current Liabilities | 1,452.00 | 1,278.00 | 1,101.08 | 1,195.55 | 1,112.46 | |
| Total Capital And Liabilities | 16,932.00 | 15,470.00 | 14,438.77 | 13,374.71 | 10,774.07 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 5,438.00 | 4,735.00 | 4,717.32 | 4,317.56 | 3,698.92 | |
| Intangible Assets | 4.00 | 4.00 | 5.28 | 7.49 | 4.95 | |
| Capital Work-In-Progress | 1,022.00 | 778.00 | 211.88 | 469.93 | 710.62 | |
| Fixed Assets | 6,464.00 | 5,517.00 | 4,934.48 | 4,794.98 | 4,414.49 | |
| Non-Current Investments | 65.00 | 82.00 | 77.05 | 72.01 | 0.01 | |
| Deferred Tax Assets [Net] | 11.00 | 10.00 | 14.24 | 14.47 | 3.23 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 55.33 | |
| Other Non-Current Assets | 311.00 | 186.00 | 101.26 | 141.75 | 126.30 | |
| Total Non-Current Assets | 6,851.00 | 5,795.00 | 5,127.03 | 5,023.21 | 4,599.36 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 3,236.00 | 3,184.00 | 3,000.41 | 2,828.62 | 2,145.23 | |
| Trade Receivables | 2,731.00 | 2,156.00 | 1,792.53 | 2,423.88 | 1,676.52 | |
| Cash And Cash Equivalents | 3,715.00 | 3,980.00 | 4,213.09 | 2,818.88 | 2,156.03 | |
| Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| OtherCurrentAssets | 399.00 | 355.00 | 305.71 | 280.12 | 196.93 | |
| Total Current Assets | 10,081.00 | 9,675.00 | 9,311.74 | 8,351.50 | 6,174.71 | |
| Total Assets | 16,932.00 | 15,470.00 | 14,438.77 | 13,374.71 | 10,774.07 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 1,841.00 | 1,432.00 | 736.98 | 1,259.90 | 1,107.13 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 39.67 | 39.67 | 39.67 | 39.67 | 39.67 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Current Investments Unquoted Book Value | 65.00 | 82.00 | 77.05 | 72.01 | 0.01 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Neutral Divis Laboratories; target of Rs 6925: Motilal Oswal
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill